eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 117 blog entries.
25 09, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-09-25T13:50:24+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., September 25, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City. Cantor Fitzgerald 4th [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-09-25T13:50:24+00:00
24 09, 2018

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018

2018-09-24T18:58:05+00:00

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection PALO ALTO, Calif., September 24, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the receipt [...]

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 20182018-09-24T18:58:05+00:00
4 09, 2018

Eiger Announces Positive Meeting with FDA on Progeria

2018-09-04T14:32:10+00:00

Eiger Announces Positive Meeting with FDA on Progeria -  Company advancing plans to file NDA for Lonafarnib in ProgeriaPALO ALTO, Calif., September 4, 2018 – Today, Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a company focused on the development and commercialization of targeted therapies for rare diseases, announced it has received minutes from a pre-investigational new drug [...]

Eiger Announces Positive Meeting with FDA on Progeria2018-09-04T14:32:10+00:00
27 08, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-08-29T18:26:56+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., August 27, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that members of the Eiger management team will participate in multiple investor conferences in September in New York City. Details of [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-08-29T18:26:56+00:00
13 08, 2018

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia

2018-08-13T16:53:51+00:00

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia PALO ALTO, Calif., August 13, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study.  [...]

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia2018-08-13T16:53:51+00:00
10 08, 2018

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results

2018-08-10T13:36:31+00:00

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results  PALO ALTO, Calif., August 10, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months ended June 30, 2018 and provided a business update. Key Achievements 2Q 2018 To [...]

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results2018-08-10T13:36:31+00:00
6 08, 2018

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health

2018-08-06T16:55:38+00:00

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health PALO ALTO, Calif., August 6, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the [...]

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health2018-08-06T16:55:38+00:00
31 07, 2018

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection

2018-07-31T12:17:12+00:00

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection PALO ALTO, Calif., July 31, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has received the [...]

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection2018-07-31T12:17:12+00:00
4 06, 2018

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™

2018-06-04T15:46:20+00:00

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ PALO ALTO, Calif., June 4, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation [...]

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™2018-06-04T15:46:20+00:00
30 05, 2018

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference

2018-05-30T22:08:39+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference PALO ALTO, Calif. – May 30, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory, President and CEO, will present a corporate update at Jefferies 2018 Global Healthcare Conference [...]

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference2018-05-30T22:08:39+00:00

About Us

EigerBio Logo

We are a values-driven company that works to embody Integrity, Passion, Accountability, Creativity, and Teamwork in the pursuit of our mission.

Privacy Policy | Terms & Conditions

Therapeutic Areas

Hepatitis Delta
Post-bariatric Hypoglycemia
Lymphedema
Hutchinson-Gilford Progeria Syndrome
Home
About Eiger
Pipeline
News
Investors
Careers
Contact Us

Contact

Eiger BioPharmaceuticals, Inc.
2155 Park Boulevard
Palo Alto, CA 94306

Phone: 1-877-899-2051
Fax: 650-618-1621
Email: info@eigerbio.com

Click Here for Directions

Eiger BioPharmaceuticals © 2018 | All Rights Reserved
Toggle Sliding Bar Area